bioAffinity Technologies (BIAF) Net Cash Flow (2021 - 2026)

bioAffinity Technologies has disclosed Net Cash Flow across 6 years of filings, most recently posting -$3.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 407.34% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at $2.7 million (up 232.12% YoY), while the FY2025 annual figure was $5.3 million, up 411.4% from the prior year.
• Net Cash Flow retreated to -$3.4 million in Q1 2026, from -$1.2 million in the prior quarter.
• Over the last five years, Net Cash Flow for BIAF reached as high as $13.3 million in Q3 2022 and fell as low as -$3.8 million in Q3 2023.
• The 5-year median for Net Cash Flow is -$813630.0 (2022), against an average of $115159.7.
• The widest YoY moves for Net Cash Flow: up 15450.34% in 2025, down 449.69% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$1.9 million in 2022, then climbed by 9.47% to -$1.7 million in 2023, then soared by 120.66% to $348711.0 in 2024, then slumped by 449.69% to -$1.2 million in 2025, then sank by 174.84% to -$3.4 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$3.4 million, -$1.2 million, and $6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.